Adverum Biotechnologies, Inc.
ADVM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.15 | -0.03 | -0.68 |
| FCF Yield | -100.51% | -21.01% | -35.66% | -7.10% |
| EV / EBITDA | -0.97 | -3.71 | -2.53 | -12.78 |
| Quality | ||||
| ROIC | -94.19% | -78.20% | -53.59% | -34.36% |
| Gross Margin | -265.30% | -56.78% | 0.00% | 38.07% |
| Cash Conversion Ratio | 0.71 | 0.74 | 0.70 | 0.74 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -21.70% | – | 210.72% |
| Free Cash Flow Growth | -1.24% | 23.52% | 2.48% | -34.91% |
| Safety | ||||
| Net Debt / EBITDA | -0.24 | 0.01 | -0.26 | -0.49 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -160.87 | -124.23 | -125.13 | 168.85 |